Last updated at 26 Sep 2024 02:50 AM
Director
DIN: 07629109
Subrahmanyam Gonupalli is currently associated with 2 companies in various capacities such as Director and Individual Promoter. They serve as a Director at HANDAN PHARMACEUTICALS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 07629109.Subrahmanyam Gonupalli is currently involved in 2 different roles. Their most recent position is with TRIQ PHARMACEUTICALS PRIVATE LIMITED as a Director. The first company Subrahmanyam Gonupalli was appointed to as a director was HANDAN PHARMACEUTICALS PRIVATE LIMITED. Subrahmanyam Gonupalli is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Subrahmanyam Gonupalli is currently associated with 2 companies in various capacities such as Director and Individual Promoter. They serve as a Director at HANDAN PHARMACEUTICALS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 07629109.Subrahmanyam Gonupalli is currently involved in 2 different roles. Their most recent position is with TRIQ PHARMACEUTICALS PRIVATE LIMITED as a Director. The first company Subrahmanyam Gonupalli was appointed to as a director was HANDAN PHARMACEUTICALS PRIVATE LIMITED. Subrahmanyam Gonupalli is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (0)
1y 10m 11 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| HANDAN PHARMACEUTICALS PRIVATE LIMITED | Director | 21-Oct-2016 |
| HANDAN PHARMACEUTICALS PRIVATE LIMITED | Individual Promoter | 21-Oct-2016 |
| TRIQ PHARMACEUTICALS PRIVATE LIMITED | Director | 04-Sep-2024 |